Targeting cell cycle is a new emerging strategy that was particularly effective in luminal-like breast cancer in reverting endocrine resistance [93], but interesting data suggest a possible role of CDK4–6 inhibitors also as chemo-companions, since CDK6 may interfere with Pt-induced cell death through FOXO3 [94]. Here, CDK6 is linked to breast carcinoma.